Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer withdraws sickle cell drug Oxbryta
Pfizer withdraws Oxbryta from global markets, cites safety concerns
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
Pfizer pulls sickle cell drug oxbryta, raising safety concerns
Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.
Pfizer to Withdraw Sickle Cell Drug Oxbryta Lots from World-Wide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.
2d
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
23h
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
STAT
5d
Sickle cell community scrambles to find safe plan after a drug is pulled from the market
There wasn’t evidence that
Oxbryta
was necessarily the cause — in some cases, malaria or another infection was involved — but according to
Pfizer
, there was an “imbalance” in deaths and ...
6d
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
devdiscourse
5d
Current Updates: Major Developments in Health Sector
This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback